INVO News and Press, INVO BioScience Inc. From 04/16/24

SARASOTA, Fla., April 16, 2024 (GLOBE NEWSWIRE) -- INVO Bioscience, Inc. (Nasdaq: INVO) ("INVO" or the "Company"), a healthcare services fertility company focused on expanding access to advanced treatment worldwide through the establishment and acquisition of fertility clinics, and with the intra...

2024-01-23 08:14:16 ET More on INVO BioScience INVO, NAYA announce new board members ahead of merger Seeking Alpha’s Quant Rating on INVO BioScience Historical earnings data for INVO BioScience Financial information for INVO BioScience Read t...

NAYA to accelerate Phase II clinical development and Early Patient Access after initial safety demonstrated in 28-patient clinical trial Program developed by Florida Biotechnologies, Inc. & the University of Miami’s Bascom Palmer Eye Institute NAYA continuing to implement acqui...

2024-01-17 12:48:13 ET More on INVO BioScience Invo to acquire Naya Biosciences in all-stock deal Seeking Alpha’s Quant Rating on INVO BioScience Historical earnings data for INVO BioScience Financial information for INVO BioScience For further...

INVO (NASDAQ: INVO ) and NAYA Biosciences expect to close their previously announced merger in the first quarter of 2024 Experienced, entrepreneurial leadership team to help structure merged public company and accelerate growth SARASOTA, Fla. and AVENTURA, Fla., Jan. 17, 2024 (GLOBE...

NAYA Biosciences Announces Publication of New Data for its CD38-targeted Flex-NK™ Bispecific Antibody in the American Society of Hematology's Blood Journal PR Newswire Abstract from 2023 American Society of Hematology (ASH) Meeting Data demonstrates differentiated p...

2023-12-06 14:49:43 ET More on INVO BioScience Invo to acquire Naya Biosciences in all-stock deal Seeking Alpha’s Quant Rating on INVO BioScience Historical earnings data for INVO BioScience Financial information for INVO BioScience For further...

NAYA Biosciences and ONK Therapeutics Announce Research Partnership to Advance Combination Therapy of FLEX-NK™ Bispecific Antibodies and Optimally Engineered Off-the-Shelf Natural Killer Cell Therapies PR Newswire NAYA Biosciences and ONK Therapeutics to assess proof-of...

2023-11-28 09:30:33 ET More on INVO BioScience Invo to acquire Naya Biosciences in all-stock deal Seeking Alpha’s Quant Rating on INVO BioScience Historical earnings data for INVO BioScience Financial information for INVO BioScience For further...

INVO Bioscience Regains Compliance with Nasdaq Minimum Stockholders' Equity Requirement PR Newswire SARASOTA, Fla. , Nov. 28, 2023 /PRNewswire/ -- INVO Bioscience, Inc. (Nasdaq: INVO) ("INVO" or the "Company"), a healthcare services company focused on expanding a...